DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA) a biopharmaceutical company focused on the
development of novel treatments for diabetes announces that the Company has
received the 2011 Emerging Company of the Year Award from the Life Science
Association of Manitoba (LSAM). The Life Science Association of Manitoba
represents the provinces biotechnology, pharmaceutical, medical device and
health products industries. 


The Emerging Life Science Company of the Year award celebrates a company based
in Manitoba that is recognized for their growth potential. They will have
distinguished themselves from their peers with demonstrated technology
innovation and achievement of milestones.


LSAM builds and supports the industries through: Sector Promotion, Training and
Advocacy. The Association's annual awards recognize leaders and innovators of
the life science community.


The Company also announced that it has issued 520,000 stock options to officers
and directors under the terms of the Company's stock option plan. The options
have an exercise price of $1.15 and a term of 10 years. The grant of options is
subject to acceptance by the TSX Venture Exchange.


About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically-unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells and 3)
improving glucose control.


DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the
enzyme glycogen synthase kinase 3 beta (GSK3B). In pre-clinical studies, DM-204
significantly improved glucose control and decreased blood pressure.

The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. 

Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024